- Home
- SNT vs EQ Comparison
SNT vs EQ Comparison
Compare SNT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- EQ
- Stock Information
- Founded
- SNT 1965
- EQ 2017
- Country
- SNT Canada
- EQ United States
- Employees
- SNT N/A
- EQ N/A
- Industry
- SNT Telecommunications Equipment
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- EQ Health Care
- Exchange
- SNT Nasdaq
- EQ Nasdaq
- Market Cap
- SNT 36.6M
- EQ 39.0M
- IPO Year
- SNT 1993
- EQ 2018
- Fundamental
- Price
- SNT $2.64
- EQ $0.71
- Analyst Decision
- SNT
- EQ Buy
- Analyst Count
- SNT 0
- EQ 2
- Target Price
- SNT N/A
- EQ $5.00
- AVG Volume (30 Days)
- SNT 83.8K
- EQ 311.1K
- Earning Date
- SNT 11-12-2024
- EQ 11-13-2024
- Dividend Yield
- SNT N/A
- EQ N/A
- EPS Growth
- SNT N/A
- EQ N/A
- EPS
- SNT 0.05
- EQ N/A
- Revenue
- SNT $34,455,000.00
- EQ $45,914,000.00
- Revenue This Year
- SNT N/A
- EQ N/A
- Revenue Next Year
- SNT N/A
- EQ N/A
- P/E Ratio
- SNT $52.60
- EQ N/A
- Revenue Growth
- SNT 2.04
- EQ 7.70
- 52 Week Low
- SNT $1.08
- EQ $0.48
- 52 Week High
- SNT $2.64
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- SNT 92.07
- EQ 39.09
- Support Level
- SNT $2.24
- EQ $0.68
- Resistance Level
- SNT $2.50
- EQ $0.89
- Average True Range (ATR)
- SNT 0.15
- EQ 0.11
- MACD
- SNT 0.12
- EQ -0.03
- Stochastic Oscillator
- SNT 100.00
- EQ 5.49
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.